These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34731493)

  • 1. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.
    Ruiz-Villaverde R; Vasquez-Chinchay F; Rodriguez-Fernandez-Freire L; C Armario-Hita J; Pérez-Gil A; Galán-Gutiérrez M
    Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
    Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
    Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Chinchay FV; Galán-Gutiérrez M
    Dermatol Ther; 2022 Oct; 35(10):e15760. PubMed ID: 35971573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
    Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
    Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
    Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
    Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
    Seidl U; Pinter A; Wilsmann-Theis D; Poortinga S; Morrison K; Mrowietz U; Gerdes S
    Dermatol Ther; 2022 Jan; 35(1):e15193. PubMed ID: 34741783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
    Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
    Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
    J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
    Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
    Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
    J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.